Stock Analysis on Net

Boston Scientific Corp. (NYSE:BSX)

This company has been moved to the archive! The financial data has not been updated since May 4, 2023.

Common Stock Valuation Ratios (Price Multiples)

Microsoft Excel

Current Valuation Ratios

Boston Scientific Corp., current price multiples

Microsoft Excel
Boston Scientific Corp. Abbott Laboratories Cigna Group CVS Health Corp. Danaher Corp. Elevance Health Inc. Humana Inc. Intuitive Surgical Inc. Medtronic PLC UnitedHealth Group Inc. Health Care Equipment & Services Health Care
Selected Financial Data
Current share price (P) $51.94
No. shares of common stock outstanding 1,437,698,101
Growth rate (g) 11.55%
 
Earnings per share (EPS) $0.45
Next year expected EPS $0.50
Operating profit per share $1.15
Sales per share $8.82
Book value per share (BVPS) $12.22
Valuation Ratios (Price Multiples)
Price to earnings (P/E) 116.31 34.46 20.56 12.03 38.95 20.15 16.81 78.20 30.79 20.38 24.32 24.03
Price to next year expected earnings 104.27 32.25 18.46 11.34 35.54 17.91 14.31 68.90 30.18 17.38 22.06 21.66
Price-earnings-growth (PEG) 10.07 5.02 1.81 1.96 4.06 1.61 0.96 5.79 15.04 1.18 2.37 2.19
Price to operating profit (P/OP) 45.28 30.44 12.44 7.30 35.51 15.85 10.42 79.58 21.10 14.09 18.19 18.63
Price to sales (P/S) 5.89 4.92 0.55 0.28 7.73 0.71 0.40 19.74 3.71 1.24 1.24 2.48
Price to book value (P/BV) 4.25 5.11 2.30 1.31 3.45 3.07 2.57 10.57 2.25 5.14 3.70 5.38

Based on: 10-K (reporting date: 2022-12-31).

If the company price multiple is lower then the price multiple of benchmark then company stock is relatively undervalued.
Otherwise, if the company price multiple is higher then the price multiple of benchmark then company stock is relatively overvalued.


Historical Valuation Ratios (Summary)

Boston Scientific Corp., historical price multiples

Microsoft Excel
Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018
Price to earnings (P/E) 105.44 63.31 11.86 33.06
Price to operating profit (P/OP) 41.05 52.01 36.71 36.68
Price to sales (P/S) 5.34 5.25 5.54 5.19 5.62
Price to book value (P/BV) 3.85 3.75 3.58 4.02 6.33

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).

Valuation ratio Description The company
P/S ratio An rationale for the P/S ratio is that sales, as the top line in an income statement, are generally less subject to distortion or manipulation than other fundamentals such as EPS or book value. Sales are also more stable than earnings and never negative. Boston Scientific Corp. P/S ratio decreased from 2020 to 2021 but then slightly increased from 2021 to 2022.
P/BV ratio The P/BV ratio is interpreted as an indicator of market judgment about the relationship between a company required rate of return and its actual rate of return. Boston Scientific Corp. P/BV ratio increased from 2020 to 2021 and from 2021 to 2022.

Price to Earnings (P/E)

Boston Scientific Corp., historical P/E calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018
No. shares of common stock outstanding1 1,434,780,104 1,426,724,712 1,417,165,707 1,396,195,349 1,385,961,926
Selected Financial Data (US$)
Net income (loss) available to common stockholders (in millions) 642 985 (115) 4,700 1,671
Earnings per share (EPS)2 0.45 0.69 -0.08 3.37 1.21
Share price1, 3 47.18 43.71 38.75 39.91 39.86
Valuation Ratio
P/E ratio4 105.44 63.31 11.86 33.06
Benchmarks
P/E Ratio, Competitors5
Abbott Laboratories 26.76 29.13 48.49 41.83
Cigna Group 13.13 13.43 8.71 13.26
CVS Health Corp. 27.53 17.39 12.88 14.15
Danaher Corp. 25.65 29.94 44.49 38.34
Elevance Health Inc. 19.20 18.13 15.87 15.96
Humana Inc. 22.52 18.34 14.48 18.10
Intuitive Surgical Inc. 64.99 59.94 87.47 48.72
Medtronic PLC 23.38 46.56 26.30 28.78 37.80
UnitedHealth Group Inc. 22.46 26.03 20.54 20.48
P/E Ratio, Sector
Health Care Equipment & Services 23.33 25.54 22.65 22.70
P/E Ratio, Industry
Health Care 21.08 21.04 28.47 21.23

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).

1 Data adjusted for splits and stock dividends.

2 2022 Calculation
EPS = Net income (loss) available to common stockholders ÷ No. shares of common stock outstanding
= 642,000,000 ÷ 1,434,780,104 = 0.45

3 Closing price as at the filing date of Boston Scientific Corp. Annual Report.

4 2022 Calculation
P/E ratio = Share price ÷ EPS
= 47.18 ÷ 0.45 = 105.44

5 Click competitor name to see calculations.


Price to Operating Profit (P/OP)

Boston Scientific Corp., historical P/OP calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018
No. shares of common stock outstanding1 1,434,780,104 1,426,724,712 1,417,165,707 1,396,195,349 1,385,961,926
Selected Financial Data (US$)
Operating income (loss) (in millions) 1,649 1,199 (80) 1,518 1,506
Operating profit per share2 1.15 0.84 -0.06 1.09 1.09
Share price1, 3 47.18 43.71 38.75 39.91 39.86
Valuation Ratio
P/OP ratio4 41.05 52.01 36.71 36.68
Benchmarks
P/OP Ratio, Competitors5
Abbott Laboratories 22.18 24.45 40.69 34.03
Cigna Group 10.40 9.08 9.03 8.38
CVS Health Corp. 14.75 10.43 6.65 7.83
Danaher Corp. 20.97 25.14 36.91 34.47
Elevance Health Inc. 15.05 15.70 12.10 13.55
Humana Inc. 16.63 17.08 9.78 15.35
Intuitive Surgical Inc. 54.49 56.11 88.37 48.89
Medtronic PLC 20.48 37.44 26.29 21.26 17.64
UnitedHealth Group Inc. 15.89 18.77 14.12 14.40
P/OP Ratio, Sector
Health Care Equipment & Services 17.45 19.20 16.88 16.21
P/OP Ratio, Industry
Health Care 16.35 17.40 21.24 17.43

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).

1 Data adjusted for splits and stock dividends.

2 2022 Calculation
Operating profit per share = Operating income (loss) ÷ No. shares of common stock outstanding
= 1,649,000,000 ÷ 1,434,780,104 = 1.15

3 Closing price as at the filing date of Boston Scientific Corp. Annual Report.

4 2022 Calculation
P/OP ratio = Share price ÷ Operating profit per share
= 47.18 ÷ 1.15 = 41.05

5 Click competitor name to see calculations.


Price to Sales (P/S)

Boston Scientific Corp., historical P/S calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018
No. shares of common stock outstanding1 1,434,780,104 1,426,724,712 1,417,165,707 1,396,195,349 1,385,961,926
Selected Financial Data (US$)
Net sales (in millions) 12,682 11,888 9,913 10,735 9,823
Sales per share2 8.84 8.33 6.99 7.69 7.09
Share price1, 3 47.18 43.71 38.75 39.91 39.86
Valuation Ratio
P/S ratio4 5.34 5.25 5.54 5.19 5.62
Benchmarks
P/S Ratio, Competitors5
Abbott Laboratories 4.25 4.78 6.30 4.83
Cigna Group 0.49 0.42 0.46 0.44
CVS Health Corp. 0.36 0.47 0.35 0.37
Danaher Corp. 5.79 6.37 7.01 6.29
Elevance Health Inc. 0.74 0.81 0.60 0.74
Humana Inc. 0.68 0.65 0.64 0.76
Intuitive Surgical Inc. 13.81 17.89 21.29 15.01
Medtronic PLC 3.72 5.57 4.36 4.36 3.92
UnitedHealth Group Inc. 1.40 1.58 1.24 1.18
P/S Ratio, Sector
Health Care Equipment & Services 1.19 1.38 1.23 1.15
P/S Ratio, Industry
Health Care 2.17 2.29 2.24 2.16

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).

1 Data adjusted for splits and stock dividends.

2 2022 Calculation
Sales per share = Net sales ÷ No. shares of common stock outstanding
= 12,682,000,000 ÷ 1,434,780,104 = 8.84

3 Closing price as at the filing date of Boston Scientific Corp. Annual Report.

4 2022 Calculation
P/S ratio = Share price ÷ Sales per share
= 47.18 ÷ 8.84 = 5.34

5 Click competitor name to see calculations.

Valuation ratio Description The company
P/S ratio An rationale for the P/S ratio is that sales, as the top line in an income statement, are generally less subject to distortion or manipulation than other fundamentals such as EPS or book value. Sales are also more stable than earnings and never negative. Boston Scientific Corp. P/S ratio decreased from 2020 to 2021 but then slightly increased from 2021 to 2022.

Price to Book Value (P/BV)

Boston Scientific Corp., historical P/BV calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018
No. shares of common stock outstanding1 1,434,780,104 1,426,724,712 1,417,165,707 1,396,195,349 1,385,961,926
Selected Financial Data (US$)
Stockholders’ equity (in millions) 17,573 16,622 15,326 13,877 8,726
Book value per share (BVPS)2 12.25 11.65 10.81 9.94 6.30
Share price1, 3 47.18 43.71 38.75 39.91 39.86
Valuation Ratio
P/BV ratio4 3.85 3.75 3.58 4.02 6.33
Benchmarks
P/BV Ratio, Competitors5
Abbott Laboratories 5.06 5.75 6.65 4.96
Cigna Group 1.95 1.53 1.46 1.49
CVS Health Corp. 1.61 1.83 1.33 1.47
Danaher Corp. 3.64 4.16 3.93 3.72
Elevance Health Inc. 3.19 3.07 2.19 2.42
Humana Inc. 4.13 3.34 3.55 4.07
Intuitive Surgical Inc. 7.78 8.59 9.53 8.13
Medtronic PLC 2.24 3.26 2.48 2.66 2.31
UnitedHealth Group Inc. 5.81 6.27 4.83 4.92
P/BV Ratio, Sector
Health Care Equipment & Services 3.55 3.81 3.28 3.14
P/BV Ratio, Industry
Health Care 4.72 4.81 4.61 4.46

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).

1 Data adjusted for splits and stock dividends.

2 2022 Calculation
BVPS = Stockholders’ equity ÷ No. shares of common stock outstanding
= 17,573,000,000 ÷ 1,434,780,104 = 12.25

3 Closing price as at the filing date of Boston Scientific Corp. Annual Report.

4 2022 Calculation
P/BV ratio = Share price ÷ BVPS
= 47.18 ÷ 12.25 = 3.85

5 Click competitor name to see calculations.

Valuation ratio Description The company
P/BV ratio The P/BV ratio is interpreted as an indicator of market judgment about the relationship between a company required rate of return and its actual rate of return. Boston Scientific Corp. P/BV ratio increased from 2020 to 2021 and from 2021 to 2022.